CTIS2023-505530-10-00招募中1 期
ong-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucel - 68284528MMY4002
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 365
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •All subjects who received cilta-cel in a Company-sponsored clinical study are candidates for Study MMY4002. The inclusion criteria for the study are described below: 1. Subjects who have received at least one dose of cilta-cel in a Company-sponsored clinical study., 2. Subjects who have provided informed consent for Study MMY4002.
排除标准
- •No exclusion criteria are applicable in this study.
研究者
相似试验
进行中（未招募）
1 期
ong-term Follow-up Study for Participants Previously Treated with Ciltacabtagene AutoleucelMultiple MyelomaEUCTR2020-005521-84-ESJanssen-Cilag International NV400
尚未招募
4 期
ong-term Follow-up Study for Participants Previously Treated with Ciltacabtagene Autoleucelplasma cell myeloma10040778Multiple MyelomaNL-OMON53393Janssen-Cilag International NV6
进行中（未招募）
1 期
ong-term Follow-up Study for Participants Previously Treated with Ciltacabtagene AutoleucelMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2020-005521-84-NLJanssen-Cilag International NV400
招募中
3 期
A Long-term Study for Participants Previously Treated with Ciltacabtagene AutoleucelMultiple MyelomaJPRN-jRCT2033220220Ei Fujikawa228
进行中（未招募）
1 期
ong term follow-up study of gene therapy trial for X-linked Retinitis PigmentosaEUCTR2018-000425-31-Outside-EU/EEAJanssen-Cilag International NV